Pregnancy Safety of Selective 5-Serotonin Reuptake Inhibitor for Depression in Women Underwent in vitro Fertilization Combined with Embryo Transfer:A Systematic Evaluation
10.6039/j.issn.1001-0408.2017.33.20
- VernacularTitle:选择性5-羟色胺再摄取抑制剂用于行体外受精联合胚胎移植术的抑郁症妇女妊娠安全性的系统评价
- Author:
Xiaoyun WANG
1
;
Xiangfen SHI
;
Jian KANG
;
Zhiyong SUN
Author Information
1. 郑州大学第一附属医院药学部
- Keywords:
Selective 5-serotonin reuptake inhibitor;
Depression;
In vitro fertilization combined with embryo tranfer;
Safety;
Meta-analysis
- From:
China Pharmacy
2017;28(33):4678-4681
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To systematically review the pregnancy safety of selective 5-serotonin reuptake inhibitor (SSRI) for depression in women underwent in vitro fertilization (IVF) combined with embryo transfer,and to provide evidence-based refer-ence. METHODS:Retrieved from PubMed,EMBase,Cochrane Library,Medline,CBM,CJFD,VIP and Wanfang database,tri-als about SSRI (trial group) vs. no medicine or placebo alone (control group) for depression in women underwent IVF combined embryo transfer were collected. Meta-analysis was performed by using Rev Man 5.3 statistical software after data extraction and quality evaluation. RESULTS:A total of 4 studies were included,involving 2122 patients. Results of Meta-analysis showed there was no statistical significance in miscarriage rate [RR=0.90,95%CI(0.61,1.35),P=0.62],pregnancy rate [RR=1.03,95%CI (0.73,1.45),P=0.87] or live birth rate [RR=1.03,95%CI(0.65,1.63),P=0.91] between 2 groups. CONCLUSIONS:For depres-sion in women underwent IVF combined with embryo transfer,SSRI do not increase miscarriage rate,decrease pregnancy rate and live birth rate and have no significant effect on the results of IVF combined with embryo transfer.
